⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NBIX News
Neurocrine Biosciences Inc
TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
XOMA
AZN
MRK
BMY
AMGN
GSK
TLRY
NBIX
Neurocrine Biosciences Presents New Analysis Establishing Benchmark for Clinically Meaningful Change in Overall Health Reported by Patients with Tardive Dyskinesia
prnewswire.com
NBIX
Neurocrine Biosciences Announces Publication in Orphanet Journal of Rare Diseases Advancing Understanding of Hyperphagia in Prader-Willi Syndrome
prnewswire.com
NBIX
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
globenewswire.com
NTHI
NBIX
ACAD
AVXL
MRK
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-'567 in Adults with Alzheimer's Disease
prnewswire.com
NBIX
Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia
prnewswire.com
NBIX
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
prnewswire.com
NBIX
Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight
prnewswire.com
TEVA
RVPH
NBIX
ALKS
VNDA
JNJ
Parkinson's Disease Market Poised for Expansion During the Forecast Period (2026-2036) Amid JUVMO Approval and Emerging Therapeutic Innovations | DelveInsight
prnewswire.com
ABBV
ANVS
ACIU
BHF
MGNX
NBIX
UCB
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
prnewswire.com
NBIX